These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 12505572)

  • 1. QTc-prolonging drugs and hospitalizations for cardiac arrhythmias.
    De Bruin ML; Hoes AW; Leufkens HG
    Am J Cardiol; 2003 Jan; 91(1):59-62. PubMed ID: 12505572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In-hospital cardiac arrest is associated with use of non-antiarrhythmic QTc-prolonging drugs.
    De Bruin ML; Langendijk PN; Koopmans RP; Wilde AA; Leufkens HG; Hoes AW
    Br J Clin Pharmacol; 2007 Feb; 63(2):216-23. PubMed ID: 16869820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-cardiac QTc-prolonging drugs and the risk of sudden cardiac death.
    Straus SM; Sturkenboom MC; Bleumink GS; Dieleman JP; van der Lei J; de Graeff PA; Kingma JH; Stricker BH
    Eur Heart J; 2005 Oct; 26(19):2007-12. PubMed ID: 15888497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Underuse of ECG monitoring in oncology patients receiving QT-interval prolonging drugs.
    Pezo RC; Yan AT; Earle C; Chan KK
    Heart; 2019 Nov; 105(21):1649-1655. PubMed ID: 31129611
    [TBL] [Abstract][Full Text] [Related]  

  • 5. QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience.
    De Ponti F; Poluzzi E; Montanaro N
    Eur J Clin Pharmacol; 2000 Apr; 56(1):1-18. PubMed ID: 10853872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Frequency of use of QT-interval prolonging drugs in psychiatry in Belgium.
    Vandael E; Marynissen T; Reyntens J; Spriet I; Vandenberghe J; Willems R; Foulon V
    Int J Clin Pharm; 2014 Aug; 36(4):757-65. PubMed ID: 24805801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [QTc-prolonging drugs and the risk of sudden death].
    Reingardiene D; Vilcinskaite J
    Medicina (Kaunas); 2007; 43(4):347-53. PubMed ID: 17485963
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of non-antiarrhythmic drugs that prolong the QT interval or induce torsade de pointes: an overview.
    De Ponti F; Poluzzi E; Cavalli A; Recanatini M; Montanaro N
    Drug Saf; 2002; 25(4):263-86. PubMed ID: 11994029
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk of serious cardiac arrhythmias among cisapride users in the United Kingdom and Canada.
    Walker AM; Szneke P; Weatherby LB; Dicker LW; Lanza LL; Loughlin JE; Yee CL; Dreyer NA
    Am J Med; 1999 Oct; 107(4):356-62. PubMed ID: 10527038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long QT syndrome caused by noncardiac drugs.
    Viskin S; Justo D; Halkin A; Zeltser D
    Prog Cardiovasc Dis; 2003; 45(5):415-27. PubMed ID: 12704598
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conventional and atypical antipsychotics and the risk of hospitalization for ventricular arrhythmias or cardiac arrest.
    Liperoti R; Gambassi G; Lapane KL; Chiang C; Pedone C; Mor V; Bernabei R
    Arch Intern Med; 2005 Mar; 165(6):696-701. PubMed ID: 15795349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced proarrhythmia and use of QTc-prolonging agents: clues for clinicians.
    Heist EK; Ruskin JN
    Heart Rhythm; 2005 Nov; 2(2 Suppl):S1-8. PubMed ID: 16253926
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Examination of QTc Values in Critically Ill Patients Diagnosed with Delirium and Prescribed Atypical Antipsychotics.
    Palazzolo N; Kram B; Muzyk AJ
    Curr Drug Saf; 2017; 12(1):32-38. PubMed ID: 27527528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data.
    Meid AD; von Medem A; Heider D; Adler JB; Günster C; Seidling HM; Quinzler R; König HH; Haefeli WE
    Drug Saf; 2017 Feb; 40(2):133-144. PubMed ID: 27896662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. QTc prolongation with antipsychotics: is routine ECG monitoring recommended?
    Shah AA; Aftab A; Coverdale J
    J Psychiatr Pract; 2014 May; 20(3):196-206. PubMed ID: 24847993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Minimizing the risks associated with QTc prolongation in people with schizophrenia. A consensus statement by the Cardiac Safety in Schizophrenia Group].
    Ames D; Camm J; Cook P; Falkai P; Gury C; Hurley R; Johnson G; Piepho R; Vieweg V;
    Encephale; 2002; 28(6 Pt 1):552-62. PubMed ID: 12506268
    [TBL] [Abstract][Full Text] [Related]  

  • 17. QTc prolongation, torsades de pointes, and psychotropic medications.
    Beach SR; Celano CM; Noseworthy PA; Januzzi JL; Huffman JC
    Psychosomatics; 2013; 54(1):1-13. PubMed ID: 23295003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survey of the use of domperidone and the association with QTc prolongation in general practice.
    Ioannou A; Jain A; Kassianos G; Missouris C
    Postgrad Med J; 2016 Jul; 92(1089):390-2. PubMed ID: 26802127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Methadone Therapy in Underserved Urban Community: QTc Prolongation and Life-Threatening Ventricular Arrhythmias.
    Chowdhury M; Wong J; Cheng A; Khilkin M; Palma E
    Cardiovasc Ther; 2015 Jun; 33(3):127-33. PubMed ID: 25825202
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The proarrhythmogenic activity of non-anti-arrhythmia drugs. Is treatment with antihistamines and cisapride safe?].
    Pelov R; Tankova L; Krushkov I
    Vutr Boles; 1999; 31(2-3):5-9. PubMed ID: 10847134
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.